Astellas Venture Management

Investor type Micro VC

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 52
Average round size
info
The average size of a deal this fund participated in
$25M
Portfolio companies 34
Rounds per year 3.06
Lead investments 4
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.35
Exits 10
Key employees Soon
Stages of investment
Early Stage Venture
Late Stage Venture
Private Equity

Areas of investment

  • Biotechnology
  • Health Care
  • Therapeutics
  • Medical
  • Pharmaceutical
Summary

Astellas Venture Management is the famous Corporate Investor, which was founded in 2005. The company was established in North America in United States. The main office of represented Corporate Investor is situated in the Menlo Park.

The typical case for the fund is to invest in rounds with 5-6 participants. Despite the Astellas Venture Management, startups are often financed by MPM Capital, U.S. Venture Partners (USVP), SR One. The meaningful sponsors for the fund in investment in the same round are MPM Capital, U.S. Venture Partners (USVP), SR One. In the next rounds fund is usually obtained by Novartis Venture Fund, SR One, MPM Capital.

The real fund results show that this Corporate Investor is 6 percentage points less often commits exit comparing to other companies. The increased amount of exits for fund were in 2018. The common things for fund are deals in the range of 10 - 50 millions dollars. The fund is constantly included in 2-6 investment rounds annually. Opposing the other organizations, this Astellas Venture Management works on 4 percentage points less the average amount of lead investments. The important activity for fund was in 2014. Despite it in 2019 the fund had an activity.

The fund has no specific favorite in a number of founders of portfolio startups. When startup sums 4 or 5+ of the founder, the probability for it to get the investment is little. Moreover, a startup needs to be at the age of 4-5 years to get the investment from the fund. Among the most popular fund investment industries, there are Medical Device, Food and Beverage. For fund there is a match between the location of its establishment and the land of its numerous investments - United States. Among the most popular portfolio startups of the fund, we may highlight F2G, Twentyeight-Seven Therapeutics, Tizona Therapeutics.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Astellas Venture Management:
Typical Co-investors
Astellas Venture Management is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Astellas Venture Management:

Funds with similar focus

Funds from United States
Funds with similar focus located in United States:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

turn.bio

Biotechnology
11 Apr 2022 Mountain View, California, United States

Mogrify

Big Data
Bioinformatics
Biotechnology
Health Care
Life Science
Therapeutics
$17M04 May 2021 Cambridge, England, United Kingdom

PhoreMost

Biopharma
Biotechnology
Health Care
$45M23 Mar 2021 Cambridge, England, United Kingdom

NeoPhore

Biotechnology
Simulation
Therapeutics
Translation Service
$20M09 Mar 2021 Cambridge, England, United Kingdom

Biotechnology
Medical
Pharmaceutical
Therapeutics
$80M24 Feb 2021 Cambridge, Massachusetts, United States

Jupiter Therapeutics

Biotechnology
Health Care
Therapeutics
14 Dec 2020 San Francisco, California, United States

Catamaran Bio

Biopharma
Biotechnology
$42M23 Nov 2020 Cambridge, Massachusetts, United States

Fukushima SiC Applied Engineering

Industrial
Manufacturing
Semiconductor
$28M07 Sep 2020 Fukushima, Fukushima Prefecture, Japan

TScan Therapeutics

Biotechnology
Health Care
Pharmaceutical
Therapeutics
$35M10 Jan 2020 Massachusetts, United States
News
PhoreMost Raises $46M in Series B Financing

– PhoreMost is a Cambridge, England, UK-based biopharmaceutical company.
– The company raised $46m in Series B funding.
– The round was led by BGF, and included new investor – XtalPi Inc., Astellas Venture Management, Trend Investment Group, and o2h ventures.
– Existing investors Parkwalk Advisors, Morningside Ventures, and Jonathan Milner also contributed.

NeoPhore Closes £15.2M Series B Funding Round

– NeoPhore is a Cambridge, UK-based small molecule neoantigen immuno-oncology company.
– Series B funding round closed.
– The round was led by Claris Ventures with participation from 2Invest, 3B Future Health Fund and Astellas Venture Management alongside founding investor the CRT Pioneer Fund.
– The new investment will be used to advance the company’s drug discovery pipeline.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Astellas Venture Management?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: